

Neopharm, Incorporated.

[View the current Neopharm, Incorporated. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32721-Neopharm%2C+Incorporated..html)

(<http://www.bioportfolio.com/biocorporate/32721-Neopharm%2C+Incorporated..html>)

Contact Details:

1850 Lakeside Dr.
Waukegan
IL
60085
United States of America

Tel: 847-887-0800

Fax: 847-887-9281

Email:

Press Releases on Neopharm, Incorporated.:

H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics	20th November, 2009	Quest Diagnostics Incorporated	<i>-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during</i>
New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)	20th November, 2009	Quest Diagnostics Incorporated	<i>MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,</i>
Spherix Announces the Closing of \$6.3 Million Registered Direct Offering	19th November, 2009	Spherix Incorporated	<i>BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting</i>

[Spherix Announces Results of Annual Shareholders Meeting](#)

19th November, 2009

Spherix Incorporated

-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants

[Give Your Pooch the Gift of Wisdom This Holiday](#)

19th November, 2009

Mars Veterinary

ROCKVILLE, Md., Nov. 19 /PRNewswire/ -- There is no greater love than the adoration you receive from man's best friend. This holiday season, return the love by gifting your four legged friend

BioNews Results for Neopharm, Incorporated.



- [NeoPharm Submits Frontline Pancreatic Cancer Treatment](#)
Pharmaceutical Technology: Oct 30 2009 3:45PM Matching: neopharm
- [BiomedReports: News and FDA Updates for NPS \(Nasdaq:NPSP\), NeoPharm \(OTC:NEOL\), ArQule \(NASDAQ:ARQL\), Phase Forward \(NASDAQ:PFWD\)](#)
Individual.com: Oct 30 2009 2:25PM Matching: neopharm
- [NeoPharm Names Dr. Aquilur Rahman as President and CEO](#)
Yahoo! Canada: Oct 29 2009 2:12PM Matching: neopharm
- [NeoPharm Names Dr. Aquilur Rahman as President and CEO](#)
Pharma Live: Oct 29 2009 8:22PM Matching: neopharm
- [NeoPharm Names Dr. Aquilur Rahman as President and CEO](#)
Genetic Engineering News: Oct 29 2009 1:48PM Matching: neopharm
- [NeoPharm Names Dr. Aquilur Rahman as President and CEO](#)
Individual.com: Oct 29 2009 5:36PM Matching: neopharm
- [Updates for Columbia \(Nasdaq:CBRX\), Alkermes \(NASDAQ:ALKS\), POZEN \(NASDAQ:POZN\), NeoPharm \(OTC:NEOL\)](#)
American Chronicle: Oct 29 2009 5:16PM Matching: neopharm
- [Updates for Columbia \(Nasdaq:CBRX\), Alkermes \(NASDAQ:ALKS\), POZEN \(NASDAQ:POZN\), NeoPharm \(OTC:NEOL\)](#)
Los Angeles Chronicle: Oct 29 2009 8:18AM Matching: neopharm
- [BiomedReports: News and FDA Updates for Columbia \(Nasdaq:CBRX\), Alkermes \(NASDAQ:ALKS\), POZEN \(NASDAQ:POZN\), NeoPharm \(OTC:NEOL\)](#)
Individual.com: Oct 29 2009 1:07AM Matching: neopharm
- [NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Me](#)
Pharma Live: Oct 28 2009 12:26AM Matching: neopharm
- [NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Me](#)
PharmiWeb: Oct 28 2009 4:42PM Matching: neopharm
- [NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally](#)

[Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment](#)

SmartBrief: Oct 28 2009 8:12AM Matching: neopharm

- [NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment](#)
Individual.com: Oct 28 2009 9:59AM Matching: neopharm
- [NeoPharm submits application with FDA for Phase II study of LE-DT for locally advanced or metastatic pancreatic](#)
Therapeutics Daily: Oct 28 2009 1:27AM Matching: neopharm
- [NeoPharma Submits Frontline Pancreatic Cancer Treatment](#)
Pharmaceutical Technology: Oct 28 2009 11:10AM Matching: neopharm



Neopharm, Incorporated. Patents:

- 7462739- [Ceramide derivatives, method for preparing the same, and therapeutic agent for treating atopic dermatitis comprising the ceramide derivatives](#)
- 7390502- [SN-38 lipid complexes and their methods of use](#)
- 7314637- [Method of administering liposomal encapsulated taxane](#)
- 7262173- [Chemosensitizing with liposomes containing oligonucleotides](#)
- 7122553- [Liposomal formulation of irinotecan](#)
- 6461637- [Method of administering liposomal encapsulated taxane](#)
- 6146659- [Method of administering liposomal encapsulated taxane](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months

old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

